Association between IL-1R2 polymorphisms and lung cancer risk in the Chinese Han population: A case-control study.

BackgroundInterleukin-1 receptor 2 (IL-1R2), as an anti-inflammatory cytokine, is involved in the pathogenesis and progression of lung cancer. However, the role of IL-1R2 polymorphisms in patients with lung cancer has yet to be fully elucidated. MethodsSix single-nucleotide polymorphisms (SNPs) in IL-1R2 were genotyped in 259 patients and 346 healthy controls. We used the chi-squared test, genetic model analysis, Haploview analysis, and multifactor dimensionality reduction (MDR) to evaluate the potential association between IL-1R2 polymorphisms and lung cancer susceptibility. Bioinformatics analyses were conducted to analyze the expression level of IL-1R2 and its association with the overall survival of lung cancer. ResultsOur results found that rs3218977-GG was associated with a decreased risk of lung cancer (odds ratio [OR]=0.39; 95% confidence interval [CI]: 0.17-0.87; p=0.023), and rs2072472 had a significant risk-increasing effect in the dominant model (AG+GG vs. AA: OR=1.54; 95% CI: 1.09-2.20; p=0.015). The MDR model also revealed that rs2072472 is the most influential risk factor of lung cancer (testing accuracy=0.543; cross-validation consistency=10/10; p=0.032). In addition, our results indicated that the IL-1R2 mRNA level was downregulated in lung cancer patients, whereas the high expression of IL-1R2 was related to a poor prognosis in lung cancer. ConclusionsOur results suggest that genetic variants of IL-1R2 may play a role in lung cancer susceptibility. Further population and functional validations of our findings are warranted.